
    
      Raltitrexed is an antifolate thymidylate synthase inhibitor that has shown efficacy and good
      safety profile in the treatment of colorectal cancer. To our knowledge, there has been no
      study published with the Raltitrexed and Paclitaxel regimen as second-line chemotherapy for
      patients with unresectable or metastatic gastric or gastroesophageal junction
      adenocarcinoma.The aim of our study was to evaluate the efficacy, safety and survival of this
      regimen in patients with unresectable or metastatic gastric or gastroesophageal junction
      adenocarcinoma.
    
  